Rickets in pediatrics due to vitamin D deficiency is still considering a major problem even in sunny and tropical countries. The prevalence of vitamin D deficiency and insufficiency in children between 6 and 15 years of age in the Kingdom of Saudi Arabia is 95.4%. Vitamin D requires two steps of hydroxylation to be functionally active. The first hydroxylation step occur in the liver by 25-hydroxylase encoded by CYP2R1 gene (11p15.2) to produce 25(OH)D3 and the second step of hydroxylation occur in proximal convoluted tubules in kidney by 1α-hydroxylase encoded by CYP27B1 gene (12q13.1) to produce hormonally active 1,25-dihydroxyvitamin D3 (1α,25(OH)2D3). Vitamin D-dependent rickets type 1B (VDDR1B) is a form of rickets due to mutation in CYP2R1 gene. Until today, only five mutations were found to affect CYP2R1 gene which lead to abnormal structure and function of 25-hydroxylase enzyme. Presence of symptoms of vitamin D deficiency in good dietary history with poor response or depending on regular to high dose of vitamin D2 or D3 to maintain 25(OH)D3 level should raise the suspicion of genetic causes of CYP2R1 mutations. These mutations are inherited as autosomal recessive; the severity and response to medication depend on number of allele affected. Some of the homogenous mutation patients showed some improvement in using Calcitriol. Bypassing the first step of hydroxylation (25-hydroxylase) in liver using 25-OH-D3 (Calcifediol) as treatment lead to dramatic improvement of biochemical and radiological finding in seven recent reported cases which needs further study.
Introduction
Classical vitamin D deficiency remains the major cause of rickets among children worldwide. A combination of poor nutritional, social, and climatic conditions explains much of this deficiency. Even in sunshine countries such as Saudi Arabia, rickets remains prevalent in different age groups An understanding of the physiology of vitamin D metabolism and its action is important to know the pathology and genetic causes of vitamin D deficiency. The source of vitamin D in the body is through the conversion of 7-dehydrocholesterol to vitamin D 3 in the skin upon exposure to sunlight ultraviolet-B and through ingestion of foods containing either cholecalciferol (vitamin D 3 ) or ergocalciferol (vitamin D 2 ) or through supplements of these substances. Once produced in the skin or absorbed from the intestine, vitamin D (including D 2 and D 3 ) requires two steps of hydroxylation to be in active and physiologic form. The first hydroxylation step occurs in the liver by 25-hydroxylase (CYP2R1, 11p15.2) converting vitamin D 3 to 25(OH)D 3 and the second step of hydroxylation occur in proximal convoluted tubules in kidney by 1α-hydroxylase (CYP27B1, 12q13.1) to convert 25(OH)D 3 to hormonally active 1,25-dihydroxyvitamin D 3 (1α,25(OH) 2 D 3 ) (figure 1). The active form of vitamin D has important roles in maintaining normal calcium and phosphate level by enhancing absorption of these elements from kidney and intestine which are important in bone mineralization. Defect in any of these steps will lead to effect on calcium and phosphate hemostasis and bone mineralization that will lead to rickets in children and osteomalacia in adults 3, 4 . Defect in 1α-hydroxylase enzyme due to mutation in CYP27B1 gene resulting in defect the synthesis of active form of vitamin D (1α,25(OH) 2 D 3 ), this condition called Vitamin D-dependent rickets type 1A (VDDR1A; MIM 264700). Vitamin D-dependent rickets type 1B (VDDR1B; MIM 600081) is a form of rickets due to mutation in CYP2R1 gene encoding 25-hydroxylase. Vitamin D-dependent rickets type 2A (VDDR2A; 277440) is caused by end-organ unresponsiveness of active vitamin D due to mutation Figure 1 . Metabolism of vitamin D3 in the skin, liver and kidney. 7-Dehydroxholesterol in the skin is converted in two steps and beginning with the exposure to ultraviolet light to vitamin D3, which is transported in the blood (mostly protein-bound) to the liver where the side chain is hydroxylated at the C25-position. The resulting 25(OH)D3 is the major circulating form of vitamin D. In the kidney, 25(OH) D3 is hydroxylated at either the C1-or the C24 position to form either 1a,25(OH)2D3 or 24R25(OH)2D3. The cytochrome P450 (CYP) dependent enzymes responsible for these transformations are, respectively, the 25-hydroxylase (CYP2R1), the 1a-hydroxylase (CYP27B1) and the 24R-hydroxylase (CYP24A1 or CYP24). Hepatic 25-hydroxylase is mitochondrial and microsomal enzyme that has six cytochrome P450 enzymes, three of them found in the animals (CYP2C11 in rat, CYP2D25 in pig, and CYP2J3 in rat) and the other three found in the human (CYP3A4, CYP27A1, and CYP2R1). CYP3A4 has activity to hydroxylate D 2 but not D 3 while CYP27A1 has activity to hydroxylate D 3 but not D 2 6 . CYP2R1 has high affinity to hydroxylate both D 2 and D 3 with hydroxylation activity toward D 3 equal to 26-fold higher than CYP27A1, suggesting that CYP2R1 plays the major role in vitamin D hydroxylation in humans 6, 7 .
Experimental studies
The second hydroxylation step of vitamin D is clearly to be carried out by a single enzyme, 1α-hydroxylase coded by CYP27B1. However, it is not clear if the first hydroxylation step carried out by single or multiple enzymes responsible for 25 . Also 25(OH)D 3 is reduced in heterozygous but the level is in between the wild-type and homozygous levels. On the other hand, the mice with Cyp27a1 −/− showed two-to threefold increase in 25(OH)D 3 and this finding is identical to the previous reports 8, 9 . CYP27A1 is responsible enzyme for cholesterol metabolism and bile acid synthesis but has a minimal effect on vitamin D metabolism. Mutation in CYP27A1 leads to defect in bile acid synthesis and this condition seen in patient with cerebrotendinous xanthomatosis 9, 10 . These results observed by Jinge G. Zhu et al. who supported the idea of CYP2R1 as the major and most important enzyme responsible for the first step of vitamin D hydroxylation at C-25, but not exclusive as there is another enzyme contributed to this 25 hydroxylation but to a lesser extent 8 .
Reported cases From Nigeria
The first mutation reported in CYP2R1 gene was announced by S.J. Casella et al. study in 1994 in Nigerian boy and his brother. Both had typical symptoms of rickets with no history of malabsorption. 25(OH)D level was low which improved on a high dose of vitamin D (4000 IU/day) and back to a low level with modest dose of vitamin D (1000 IU/ day). Genetic test done and showed the first mutation reported in CYP2R1 gene which is c.296T > C (L99P) 11 . Cohort study was conducted by Tom D. Thacher et al. about the prevalence of CYP2R1 mutation in Nigerian children. They found a new novel mutation in addition to the previously known reported mutation of CYP2R1 in two out of twelve families. One mutation was c.296T > C (L99P) found in 8 members of 2 generations of both families. The other mutation was c.726A > C (K242N) found in heterozygous mother of the index case in the second family 12 . These mutations effect CYP2R1 structure and function. L99P amino acid replacement will effect on CYP2R1 folding while K242N amino acid change will affect interaction surface of CYP2R1 with vitamin D 13, 14 .
The first family had L99P mutation of CYP2R1 in form of homozygous (the index case, his brother and father) and heterozygous (2 sisters and mother) with more severe rickets seen in homozygous members. In homogenous patients, index case and his brother were presented at age of 12.5 and 11 years respectively. Both were had legs deformity, bone pain, difficulty in walking, signs of rickets, and history of low calcium rich diet associated with severe biochemical and radiological picture of rickets. In heterozygous members, only one sister had a history of mild genu varum that resolved spontaneously, others were normal. The second family had heterozygous L99P mutation of CYP2R1 in index case, her sister and father. Both sisters were had typical clinical, biochemical, and radiological pictures of rickets 12 .
As seen in experimental and Al sagheir A. et al studies, 25(OH)D 3 level was low in heterozygous patients but in between the homozygous and normal 8, 12, 16 . Homozygous patients (L99P) showed no response to the treatment with 50000 IU of vitamin D compared with heterozygous patients (L99P and K242N) . They demonstrated that the incremental levels of 25(OH)D 2 and 25(OH)D 3 at day three (the peak) after supplementing D 2 and D 3 were blunted in homozygous while partial increments in heterozygous compared with control (significant P value) group. In L99P homozygous subjects, the 1,25(OH)2D was relatively low and increased with supplement of D2 and D3.12 On the other hand, the improvement in rickets clinically and radiologically were seen after using very high dose of vitamin D, 600,000 IU IM, indicating CYP2R1 mutation can be overcome by high dose of vitamin D as seen in the previous experimental study which showed low but measurable 25(OH)D 3 in Cyp2r1 -/-mice 8, 12 . This observation supporting that there might be a role of other P450 enzymes in 25 hydroxylation.
From Saudi Arabia
Two new mutations in CYP2R1 were described by Al Mutair A. N. et al. in two siblings of Saudi family. The index case was 13 years old girl first presented to clinic at age of 10 years as short stature. The second sibling was the older brother 14.7 years old who had symptoms at age of 5 years. Both siblings had bow legs, bone pain, and decrease activity in addition to difficulty in walking and other signs of rickets seen in older brother. They had normal development, nutritional, antenatal and postnatal history in addition to absent of malabsorption symptoms. Both were on vitamin D supplement at different doses and the brother used additionally calcium supplement. Initial investigation showed classical biochemical picture of vitamin D deficiency in presence of normal 1,25(OH) 2 D 3 (table 1) 15 .
Both siblings were treated with Cholecalciferol (5000 IU/day for the girl and 10,000 IU/day for the boy). As seen in table 1, the abnormal biochemical results improved with treatment except 25(OH)D 3 level ,which was increased but remain low in spite of high dose treatment, coincides with experimental study in mice 8, 15 . Serum level of 1,25(OH)2D3 remained normal with treatment reflecting normal one alfa hydroxylase enzyme activity that is under parathyroid Molecular genetic testing was done for the family and showed new not previously reported compound heterozygous mutations (figure 2) in both siblings. One mutation was inherited from the father with transition of G to A in the first nucleotide of the highly conserved splice donor sequence of intron 2 (c.367+1,G>A). This mutation will cause abnormal splice in mRNA that will cause truncated CYP2R1 protein. The second mutation was inherited from the mother with T insertion in exon 3 (c.768,insT) that alters the normal translational reading frame. This mutation will cause again truncated CYP2R1 protein. Both truncated CYP2R1 proteins lack the domains required for normal function of 25-hydroxylase enzyme. These mutations has autosomal recessive inheritance pattern (figure 2) 15 . . Two mutations were found similar to the mutations reported by Al Mutair A. N. et al: c.367+1,G>A (44.4%) and c.768,insT (55.6%), 18 patients were had homozygous mutations, and heterozygous mutations were found in 9 patients from two families with rickets (familial rickets). There were no mutation detected in 3 patients who had no family history of rickets (non familial rickets) 15, 16 .
Homozygous patients had more severe symptoms and lower 25(OH)D 3 as compared to heterozygous patients, as seen in the experimental study and the previous Saudi siblings reports 8, 15, 16 . The most clinical presentations were bone pain, limitation in activity, bone deformities and hypocalcaemia with percentage 86.2%, 58.6%, 31%, and 17.2% respectively 16 . All heterozygous patients and most of homozygous patients (72.2%) were responded to a high dose of cholecalciferol (50,000-100,000 IU/week). The remaining of homozygous patients (27.8%) were responded to Calcitriol 16 .
From France
Arnaud Molin et al. discovered a new mutation in CYP2R1 that is not previously reported (c.124_138delinsCGG [p.Gly42_Leu46delinsArg]) in one family. Interestingly, a selective 25-hydroxy vitamin D therapy (Calcifediol) was tried as treatment in difficult diagnosed patients. They described 7 patients from two unrelated families, one from France and the other from Moroccan extraction. The proband case of France family was 4 years old boy, on Cholecalciferol 1000-1200 IU/day till age of 18 months. He developed leg deformity, bone pain and hypotonia. Biochemical and radiological investigation showed typical picture of vitamin D deficiency. Initially diagnosed as VDDR1A and given Alfa calcidol which lead to partial improvement of biochemical parameters except parathyroid hormone (PTH) and alkaline phosphatase (ALP) but later he developed hypercalcaemia and hypercalciuria as complications of treatment. Once diagnosed as VDDR1B with homozygous mutation, shifted to Calcifediol (25-OH-D 3 ) which showed marked improvement in all biochemical parameters. The proband case of Moroccan family was 9 years old boy had difficulty in walking at age of 5 years. He was initially on Cholecalciferol 800 IU/day till the age of 18 months then he was put on 100,000 IU vitamin D yearly. At 7 years of age he presented with proximal muscle weakness and diagnosed as myopathy with normal muscle biopsy. Later he was found to have homozygous mutation in CYP2R1. 
Conclusion
Rickets due to vitamin D deficiency is still considered as a major problem in pediatrics even in sunny and tropical countries.
1 This problem will be more prevalent if there are multiple risk factors present together like poor nutritional, social, and climatic conditions, and it is rarely due to genetic causes. One of the genetic defects is related to 25 hydroxylase enzyme found in liver which is mainly coded by CYP2R1 gene located at chromosome 11p15.2; other genes are involved in 25-hydroxylation but to a lesser extent. CYP2R1 is responsible for normal structure and function of 25 hydroxylase enzyme 3, 4, 6, 7 .
Until today, only five mutations were found to affect CYP2R1 gene. Two mutations were reported from Nigeria 11, 12, 15, 16, 17 .
The phenotype appearance in CYP2R1 mutations (VDDR1B) seem to be more complicated and depend on the number of allele affected as compared with autosomal recessive VDDR1A 12 . Patient with one allele affect has modest low of 25(OH)D 3 and will respond to regular vitamin D supplement compared with two alleles affect patient with severe low of 25(OH)D 3 who may respond to higher dose of cholecalciferol or Calcitriol 12, 15, 16 . Using Calcifediol (25-OH-D 3 ) as treatment; will bypass the first step of hydroxylation (25-hydroxylase) in liver, which lead to dramatic improvement of biochemical and radiological finding in seven cases from a single report that may need further studies 17 .
